compounded semaglutide crackdown news october 2025 The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new (Wegovy) weight-loss pill from the FDA proposes a new GLP-1

This hormonal imbalance can contribute to the development of masculine features, such as excess facial and body hair, as well as acne and irregular menstrual cycles

Well help you bounce back fasthydrated, refreshed, and headache-free

Monitor closely for nausea, vomiting, diarrhea, abdominal pain, or signs of hypoglycemia (especially if you take insulin or sulfonylurea medications)

Unlike existing injections, it acts on GLP-1, GIP, and glucagon receptors at the same time, which is why it is described as a Retatrutide triple agonist

Factors That Affect How Quickly You'll See Results Your current weight, baseline metabolism, and starting dose all influence the timeline for visible weight loss